JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Home・Akcijų sąrašas・Avita Therapeutics Inc

Avita Therapeutics Inc

Uždarymo kaina

3.93 -2.96

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.84

Max

4.05

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.3M -13M
Pardavimai	-1.4M 17M
Pelno marža	-77.289
Darbuotojai	260
EBITDA	-3.2M -11M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+10.29% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-12

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	8.2M 129M
Ankstesnė atidarymo kaina	6.89
Ankstesnė uždarymo kaina	3.93

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

8.83 / 9.77 Palaikymas ir pasipriešinimas

Avita Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-05 23:57; UTC

Uždarbis

Naver Has Record Year Despite Weaker Final Quarter

2026-02-05 23:45; UTC

Karštos akcijos

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

2026-02-05 22:26; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

2026-02-05 22:00; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

2026-02-05 23:47; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-05 23:47; UTC

Rinkos pokalbiai

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

2026-02-05 23:43; UTC

Rinkos pokalbiai

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

2026-02-05 23:37; UTC

Rinkos pokalbiai

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

2026-02-05 23:20; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

2026-02-05 23:11; UTC

Rinkos pokalbiai

Amazon CEO Confident in Return on $200B Investment -- Market Talk

2026-02-05 23:09; UTC

Uždarbis

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

2026-02-05 23:08; UTC

Uždarbis

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

2026-02-05 23:07; UTC

Uždarbis

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

2026-02-05 23:03; UTC

Rinkos pokalbiai

Uždarbis

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

2026-02-05 23:03; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

2026-02-05 23:00; UTC

Uždarbis

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

2026-02-05 23:00; UTC

Uždarbis

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

2026-02-05 22:59; UTC

Uždarbis

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

2026-02-05 22:59; UTC

Uždarbis

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

2026-02-05 22:52; UTC

Uždarbis

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

2026-02-05 22:45; UTC

Uždarbis

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

2026-02-05 22:37; UTC

Rinkos pokalbiai

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

2026-02-05 22:11; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

2026-02-05 22:03; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

2026-02-05 22:01; UTC

Uždarbis

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

2026-02-05 21:59; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

2026-02-05 21:51; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

2026-02-05 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-02-05 21:49; UTC

Uždarbis

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

2026-02-05 21:45; UTC

Uždarbis

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Akcijų palyginimas

Kainos pokytis

Avita Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

10.29% į viršų

12 mėnesių prognozė

Vidutinis 4.5 USD 10.29%

Aukščiausias 5.5 USD

Žemiausias 3.5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Avita Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Avita Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

8.83 / 9.77Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.